EN DE

Aceso Life Science Group Ltd (0474) Fair Value & Analysis

Industrials · HK · Market cap HK$1.0B

AL Aceso Life Science Group Ltd 0474 · HK
PriceHK$0.1480
Fair ValueHK$0.0800
Upside-46.0%
Quality49/100
Watch Aceso Life Science Group Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 0.0% net margin
High debt · generates free cash flow
Trails peers (2/10)
Narrow moat 3/100
Evidence: Medium Share as image

Fair value as of: Aug 19, 2026

From 4 valuation models · updated today

Fair value updated Aug 19, 2026, revised from HK$0.0100 to HK$0.0800 (+700.0%) since Aug 13, 2026. Share price +29.8% over the past month.

Below-average quality, and screening another 46% overvalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
  • Quality 49/100 (below-average quality) with medium evidence: read the verdict with care.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$0.2300 HK$0.0180 Fair Value HK$0.0800 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

60‑month range HK$0.0180 – HK$0.2300 · the HK$0.1480 price screens above the HK$0.0800 fair value. Dashed = 300-day average. As of Aug 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aceso Life Science Group Ltd (0474) currently trades at HK$0.1480, while our model-based Fair Value estimate is HK$0.0800, implying the stock looks roughly 46.0% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Revenue grew 18.2% year over year. It earns a return on equity of -51.4%. Net debt stands at HK$2.2B. Fundamentals as of Aug 19, 2026

The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -21% fair-value upside, at -46%, 0474 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$0.0100 80
Rev-Margin DCF HK$0.0200 74
Gordon GGM HK$0.0100 HK$0.0100 70
All 4 models by family
Dividend Discount
Gordon GGM HK$0.0100 HK$0.0100 70
DDM Multi-Stage HK$0.0100 HK$0.0100 61
Growth DCF
Growth DCF HK$0.0100 80
Rev-Margin DCF HK$0.0200 74

Notify me when 0474 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) −HK$56.0M
Revenue growth (YoY) +18.2%
Return on equity -51.4%
Free cash flow HK$15.0M FY2025
Operating margin 711%
EPS (TTM) HK$-0.0500
More key figures
Net debt HK$2.2B FY2025

Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 79

Profitability 1
Margins and returns on capital today
Quality Growth 76
Are margins and returns improving?
Cashflow 57
Earnings quality: real cash, not paper profit
Fin. Strength 14
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 87
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 92
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom.

Full company description

Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of construction machinery and spare parts business; provision of repair and maintenance and transportation service business; money lending business; provision of asset management, securities brokerage and other financial service business; property leasing business; and property development business segments. The company leases and sells construction machinery, including crawler cranes, mobile cranes, aerial platforms, and foundation equipment, as well as spare parts; and sells construction materials. It also provides repair and maintenance services for construction machinery; transportation services, such as local container delivery, construction site delivery, and heavy machinery transport; mortgaged and personal loans; and money lending, asset management, commodities, futures, securities brokerage, and other financial services. In addition, the company retails men's and women's apparel; and provides group management, administration, and securities investment services. Further, the company involved in trading of futures and bioscience; and urban development businesses. The company was formerly known as Hao Tian Development Group Limited and changed its name to Aceso Life Science Group Limited in October 2020. Aceso Life Science Group Limited was founded in 1985 and is based in Wan Chai, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aceso Life Science Group Ltd reported revenue of HK$195M in FY2025 versus HK$346M in FY2021, a compound −13.4%/yr. Reported net income was −HK$895M in FY2025.

Growth Quality 16/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$195M
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−14.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.0%
Avg. growth/yr (22Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.6%
Revenue −13.4%/yr
FY21 HK$346M
FY22 HK$315M
FY23 HK$312M
FY24 HK$11.0M
FY25 HK$195M
Net income
FY21 −HK$376M
FY22 −HK$370M
FY23 −HK$264M
FY24 −HK$462M
FY25 −HK$895M

0474 screens 46% overvalued. Compare with United Rentals, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Aceso Life Science Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0474

Peer Group

Rental & Leasing Services · 98 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 51 · Above median
Fair Value upside −46% · Bottom 25%
Return on assets -17% · Bottom 25%
Net margin (TTM) 0% · Below median
Revenue growth 18% · Top 25%
Dividend yield (TTM) 0.5% · Bottom 25%
Debt / equity 46.75× · Higher than 75% of peers

Valuation Multiples vs Rental & Leasing Services median · lower = cheaper

P/B 10.73× · Pricier than 75% of peers
P/FCF 8.6× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 55
FUTURE91 · sector 18
PAST0 · sector 26
HEALTH0 · sector 69
DIVIDEND10 · sector 47

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Rental & Leasing Services stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).

Stock Price Fair Value vs Fair Value
United Rentals, Inc URI $1,129 $449.86 -60%
Sunbelt Rentals Holdings SUNB $84.80 $65.76 -22%
AerCap Holdings AER $150.25 $301.51 +101%
Ayvens AYV €11.36 €25.90 +128%
Ryder System, Inc R $262.96 $109.71 -58%
Localiza Rent a Car S.A RENT3 R$34.71 R$37.01 +7%
Element Fleet Management Corp EFN C$27.92 C$20.86 -25%
BOC Aviation Limited 2588 HK$74.40 HK$18.61 -75%
GATX Corporation GATX $177.56 $140.90 -21%
Avis Budget Group CAR $139.58 $158.11 +13%

Compare Aceso Life Science Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Aceso Life Science Group Ltd (0474) overvalued or undervalued?
As of Aug 19, 2026, our model estimates a fair value of HK$0.0800 versus a price of HK$0.1480, about −46% (overvalued).
What is the fair value of 0474?
Our model-based fair value for Aceso Life Science Group Ltd is HK$0.0800 (as of Aug 19, 2026), built from audited fundamentals. The current price: HK$0.1480.
What is the quality score of 0474?
Aceso Life Science Group Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the net profit margin of 0474?
The net profit margin of Aceso Life Science Group Ltd is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Aceso Life Science Group Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.